Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04798469 · ClinicalTrials.gov registry record · Phase 2

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

A Phase 2 study of Pain and Opioid Use, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT04798469 is a Phase 2 study of Pain and Opioid Use that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 150 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04798469, a Phase 2 study of Pain and Opioid Use, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).

Interventions

  • DRUG Placebo
  • DRUG Testosterone Undecanoate 250 MG/ML

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-01-10
Est. Completion 2027-12-30
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04798469

The ClinicalTrials.gov registry entry for NCT04798469 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (51% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04798469 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04798469 about?

NCT04798469 is a clinical study titled "Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism". The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism ...

What is the current status of trial NCT04798469?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-01-10. Estimated completion is 2027-12-30.

What conditions does trial NCT04798469 study?

This clinical trial studies the following conditions: Pain, Opioid Use, Hypogonadism, Male.

What interventions are being tested in trial NCT04798469?

The interventions under investigation include: Placebo (DRUG), Testosterone Undecanoate 250 MG/ML (DRUG).

Who is sponsoring clinical trial NCT04798469?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04798469 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.